tiprankstipranks
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
US Market
TAK
Takeda Pharmaceutical Company
RESEARCH TOOLSreports
Want to see TAK full AI Analyst Report?

Takeda Pharmaceutical Company (TAK) Stock News & Sentiment

1,352 Followers
Takeda’s SPOTLITE Study Wraps Up, Sharpening the View on Complex Fistula Care
Premium
Company Announcements
Takeda’s SPOTLITE Study Wraps Up, Sharpening the View on Complex Fistula Care
19h ago
TAK
Takeda Targets Older Adults With New Dengue Vaccine Study, Eyeing Long-Term Market Upside
Premium
Company Announcements
Takeda Targets Older Adults With New Dengue Vaccine Study, Eyeing Long-Term Market Upside
10d ago
TAK
Takeda’s TAK-505 Trial Marks a New Bet on Difficult Solid Tumors
Premium
Company Announcements
Takeda’s TAK-505 Trial Marks a New Bet on Difficult Solid Tumors
10d ago
TAK
Takeda Extends Pediatric Entyvio Data: What Long-Term Safety Tracking Means for TAK Investors
Premium
Company Announcements
Takeda Extends Pediatric Entyvio Data: What Long-Term Safety Tracking Means for TAK Investors
17d ago
TAK
Takeda’s Real-World Dengue Vaccine Study Could Reshape Its Emerging Markets Outlook
Premium
Company Announcements
Takeda’s Real-World Dengue Vaccine Study Could Reshape Its Emerging Markets Outlook
17d ago
TAK
Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push
Premium
Company Announcements
Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push
23d ago
TAK
Takeda’s Long-Term Psoriatic Arthritis Trial Could Reshape TAK’s Immunology Outlook
Premium
Company Announcements
Takeda’s Long-Term Psoriatic Arthritis Trial Could Reshape TAK’s Immunology Outlook
1M ago
TAK
More TAK News >

TAK News on the Web

Takeda Extends Pediatric Entyvio Data: What Long-Term Safety Tracking Means for TAK Investors
TipRanks News
Bullish
Takeda’s Real-World Dengue Vaccine Study Could Reshape Its Emerging Markets Outlook
TipRanks News
Bullish
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Zacks
Bullish
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
TipRanks News
Neutral
Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push
TipRanks News
Neutral
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
Zacks
Neutral
Takeda upgraded to Outperform from Market Perform at Bernstein
TipRanks News
Bullish
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Zacks
Bearish

News Score - Last 7 Days

Very Positive
TAK
Sector Average
Media Buzz
This Week3 articles
Weekly Average5.75 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TAK’s Media Buzz Sentiment?
3 articles about TAK were published this week. In an average week, 5.75 articles are published.
    What is TAK’s weekly average amount of articles?
    In an average week, 5.75 articles about TAK are published.
      What is TAK’s News Sentiment?
      100% of articles about TAK were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week